Nanobiotix SANASDAQ:NBTX
- LAST PRICE5.4100
- TODAY'S CHANGE (%)-0.0900 (-1.6364%)
- Bid / Lots2.7600/ 2
- Ask / Lots5.7300/ 15
- Open / Previous Close5.5500 / 5.5000
- Day Range
- 52 Week Range
- Volume1,565
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NBTX |
|---|---|---|
| 09:36 ET | 100 | 5.55 |
| 12:50 ET | 538 | 5.41 |
Apr 17, 2024
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024, from 4:15PM ET on Wednesday Apr 17, 2024 by Dow Jones
4:15PM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 10, 2024
Voting Rights and Shares Capital of the Company, from 4:15PM ET on Wednesday Apr 10, 2024 by Dow Jones
4:15PM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 2, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nanobiotix SA | 263.4M | -3.0x | --- |
ESSA Pharma Inc | 279.6M | -10.8x | --- |
Inozyme Pharma Inc | 278.6M | -3.3x | --- |
RAPT Therapeutics Inc | 276.7M | -2.6x | --- |
Invivyd Inc | 274.2M | -1.3x | --- |
Tevogen Bio Holdings Inc | 286.3M | -4.6x | --- |
Company Information
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Contact Information
- Headquarters
- 60 rue de WattigniesPARIS, France 75012
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Supervisory Board
- Gary Phillips
- Chairman of the Management Board, Chief Executive Officer, Co-Founder
- Laurent Levy
- Independent Vice Chairwoman of the Supervisory Board
- Anne-Marie Graffin
- Chief Financial Officer, Member of the Management Board
- Bart Van Rhijn
- Chief People Officer, Member of the Management Board
- Anne-Juliette Hermant
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $263.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 47.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.30 |
EPS | $-1.79 |
Book Value | $-0.83 |
P/E Ratio | -3.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
